Middleton, WI (September 20, 2017) – Lucigen, a leading provider of molecular biology enzymes and kits, announced the issue of U.S. Patent #9765343 for the pJAZZ® BigEasy® System, which offers the unique ability to stably reproduce large or challenging sequences of DNA. Conventional vector systems often fail to give good results with tough-to-clone DNA sequences from humans, parasites, plants, and other organisms. The pJAZZ system gives researchers the ability to study genes that were previously inaccessible. Many of these genes are related to disease pathways with potential for gene therapy. Other applications include creating novel biological products, such as bio-fuels or high-strength fibers derived from spider silk genes. Lucigen’s unique pJAZZ technology is available for licensing. For any inquiries, please email [email protected].
“We are excited about the potential of this new technology. Providing a tool allowing researchers to do something they could not do before opens the door to new discoveries and possible cures,” said Jeff Williams, President.
Lucigen Corporation is working to improve people’s lives by providing quality products and services to life science and healthcare professionals. Lucigen provides biomedical research products and services to customers worldwide, all under an ISO 13485-compliant quality system. Core competencies include enzyme evolution, protein expression, cloning, competent cells, NGS, and molecular diagnostics.